Mutations to the ATP-sensitive K + channel (K ATP channel) that reduce the sensitivity of ATP inhibition cause neonatal diabetes mellitus via suppression of b-cell glucose-stimulated free calcium activity ([Ca 2+ ] i ) and insulin secretion. Connexin-36 (Cx36) gap junctions also regulate islet electrical activity; upon knockout of Cx36, b-cells show [Ca 2+ ] i elevations at basal glucose. We hypothesized that in the presence of overactive ATP-insensitive K ATP channels, a reduction in Cx36 would allow elevations in glucose-stimulated [Ca 2+ ] i and insulin secretion to improve glucose homeostasis. To test this, we introduced a genetic knockout of Cx36 into mice that express ATP-insensitive K ATP channels and measured glucose homeostasis and islet metabolic, electrical, and insulin secretion responses. In the normal presence of Cx36, after expression of ATPinsensitive K ATP channels, blood glucose levels rapidly rose to >500 mg/dL. Islets from these mice showed reduced glucose-stimulated [Ca 2+ ] i and no insulin secretion. In mice lacking Cx36 after expression of ATP-insensitive K ATP channels, normal glucose levels were maintained. Islets from these mice had near-normal glucose-stimulated [Ca 2+ ] i and insulin secretion. We therefore demonstrate a novel mechanism by which islet function can be recovered in a monogenic model of diabetes. A reduction of gap junction coupling allows sufficient glucose-stimulated [Ca 2+ ] i and insulin secretion to prevent the emergence of diabetes. Glucose-stimulated insulin secretion from b-cells in the islet is regulated via a series of metabolic and electrical events. The ATP-sensitive K + channel (K ATP channel) provides a central role in coupling increases in the ATP/ ADP ratio after the metabolism of glucose, to membrane depolarization, elevated intracellular free calcium activity ([Ca 2+ ] i ), and insulin granule exocytosis (1). The K ATP channel is made up of inward-rectifying K + channel Kir6.2 and sulfonylurea receptor 1 (Sur1). In humans,
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Cellular interactions within the islet have long been known to be important for enhancing the regulation of insulin release (11) and are also important for regulating electrical activity (12) . Connexin-36 (Cx36) gap junction channels regulate islet electrical activity by coupling K ATP -regulated membrane depolarization between b-cells of the islet. This synchronizes oscillations in membrane depolarization and [Ca 2+ ] i at elevated glucose (13, 14) , leading to a coordination of first-phase insulin release and pulsatile second-phase insulin release (15) . Under normal conditions, Cx36 gap junction channels also enhance a suppression of spontaneous elevations in [Ca 2+ ] i at basal glucose (16, 17) ; upon a knockout of Cx36, elevated [Ca 2+ ] i is observed at lower glucose levels (14, 18) . This suppression likely occurs as a result of the longestablished presence of b-cell heterogeneity (19) , where inexcitable cells in the islet suppress membrane depolarization and [Ca 2+ ] i in more excitable cells via gap junction coupling (16, 18) .
Given +/+ and Cx36 2/2 controls) received five daily doses of tamoxifen (50 mg/g body weight) at experimental day 1-5. Blood glucose was measured daily as previously performed (3) with a glucometer (Ascensia Contour; Bayer). Plasma insulin was measured at day 29 from blood samples centrifuged at 14 krev/min for 10 min and assayed using mouse ultrasensitive insulin ELISA (Alpco). Glucose tolerance tests were performed at day 30-32. Littermate or agematched mice were fasted overnight for 16 h and received intraperitoneal injection of 2 g/kg body weight of glucose, and blood glucose was measured on tail vein blood samples preinjection (0 min) and 15, 30, 60, 90 , and 120 min post-glucose delivery. Insulin tolerance tests (ITTs) were performed at day 30-32. Littermate mice were fasted for 6 h and received intraperitoneal injection of 0.75 units/kg body weight of human recombinant insulin (Novolin; Novo Nordisk), and blood glucose was measured on tail vein blood samples preinjection (0 min) and 15, 30, 45, 60 , and 90 min postinjection.
Islet Isolation and Insulin Secretion
At day 30-36, islets were isolated from pancreata of each experimental mouse and maintained in islet medium (RPMI medium, 10% fetal bovine serum, 11 mmol/L glucose, 100 units/mL penicillin, 100 mg/mL streptomycin) at 37°C under humidified 5% CO 2 After the incubation period, the medium was removed and insulin concentration assayed using mouse ultrasensitive insulin ELISA. To estimate insulin content, islets were lysed in 1% Triton X-100 and frozen at 220°C overnight.
Microscopy
All isolated islets were imaged using established methods (13) , in polydimethylsiloxane microfluidic devices (16) , maintained at 37°C, with imaging medium (125 mmol/L NaCl, 5.7 mmol/L KCl, 2.5 mmol/L CaCl 2 , 1.2 mmol/L MgCl 2 , 10 mmol/L HEPES, 2 mmol/L glucose, 0.1% BSA, pH 7.4).
To measure [Ca 2+ ] i response and dynamics, islets were loaded with 4 mmol/L Fura Red-AM (Invitrogen) for 2 h at room temperature and imaged on a Marianas spinning-disk microscope (3I) with a 403 1.3 NA PlanNeofluar oil-immersion objective (Zeiss). Images were acquired 10 min after glucose stimulation. Fura Red was imaged using a 488-nm diode laser for excitation and a 580-to 655-nm band-pass emission filter (Semrock). GFP was imaged using a 488-nm diode laser for excitation and a 500-to 550-nm band-pass emission filter. There was no detectable cross-talk between Fura Red and GFP.
To measure [Ca 2+ ] i concentration, islets were loaded with 2 mmol/L Fura 2-AM for 30 min at room temperature and imaged on an Eclipse-Ti widefield microscope (Nikon) with a 203 0.75 NA Plan Apo objective. Images were acquired 10 min after glucose stimulation or immediately after KCl stimulation. Fura 2 was imaged sequentially using 340-and 380-nm (65 nm) Arc-lamp excitation and a 470-to 550-nm band-pass emission filter (Chroma).
To measure NAD(P)H, islets were imaged on an LSM510 microscope (Zeiss), with a 403 1.2 NA CApochromatic water-immersion objective. NAD(P)H autofluorescence was imaged with two-photon excitation using a 710-nm mode-locked Ti:sapphire laser (Coherent) and a 400-to 500-nm band-pass emission filter (Chroma) and nondescanned detector. GFP fluorescence was imaged using a 488-nm Ar + laser line for excitation and a 500-to 550-nm band-pass emission filter. Z-stacks of six images were acquired at 2-mm spacing. No GFP fluorescence was detected in the NAD(P)H channel.
To measure mitochondrial membrane potential changes, islets were loaded with 50 nmol/L Rhodamine 123 for 20 min at 37°C and imaged on an LSM510 microscope with a 403 1.2 NA C-Apochromatic waterimmersion objective. Images were acquired 10 min after glucose stimulation. Rhodamine 123 was imaged using a 488-nm Ar + laser line for excitation and a 500-to 550-nm band-pass emission filter. Z-stacks of six images were acquired at 2-mm spacing.
Image Analysis
Images collected on the different microscope systems (3I and Zeiss; Nikon) were analyzed offline in Matlab (Mathworks) using established methods (6, 18, 22) . For Fura 2, 340-and 380-nm intensities were averaged across each islet, and the "background" intensity averaged over an unstained islet subtracted. Time-averaged [Ca 2+ ] i concentration was calibrated from the backgroundsubtracted time-averaged 340-nm/380-nm intensity ratio using the Fura 2 calibration kit (Invitrogen).
NAD(P)H and Rhodamine 123 fluorescence were averaged across each islet, with Z positions corrected for focal drift. The mean NAD(P)H autofluorescence for each experimental group was normalized to the average autofluorescence in Cx36 +/+ islets at 2 mmol/L. The mean Rhodamine 123 fluorescence of each islet was normalized to the fluorescence at 2 mmol/L glucose.
To estimate the proportion of the islet showing elevations in [Ca 2+ ] i , Fura Red images were first smoothed using a 3 3 3 average filter. The variance (intensity fluctuation) was calculated over the time course of each pixel. A threshold variance was calculated for a silent cell, identified as quiescent at 2 mmol/L glucose, which represents image noise. An active area showing [Ca 2+ ] i fluctuations was defined as having a variance significantly greater (95% confidence) than the variance of the silent cell.
To determine high-GFP (GFP + ) cells, GFP images were first smoothed using a 3 3 3 average filter. A threshold intensity was calculated from the autofluorescence in the GFP channel from control (GFP 2 ) Cx36 +/+ or Cx36
islets. A GFP + region was identified as having GFP fluorescence greater than the threshold intensity. expression, ad libitum-fed blood glucose levels also rose compared with littermate control animals ( Supplementary  Fig. 1 (Fig. 3A) , with on average 50% (each ranging from 30 to 65%) of the islet GFP + (Fig. 3B) mice and control Cx36 2/2 mice after 0.075 units/kg intraperitoneal insulin injection after 0 time point. n = 13 littermate mice in each group. *Significant difference (P < 0.05, two-tailed paired Student t test) between each experimental group as indicated. Error bars represent mean 6 SEM.
RESULTS

Inducible
levels, transient elevations (oscillations) in [Ca
2+
] i were observed in Cx36 +/+ control islets (Fig. 4A, top) . These oscillations were rarely observed in Cx36 +/+ ;Kir6.2 [DN30, K185Q] islets at elevated glucose levels (Fig. 4A, middle) (Fig. 4A, bottom) ] i elevations across most of the islet (Fig. 5A, top) ] i elevations (Fig. 5A, bottom) . [Ca 2+ ] i elevations were significantly greater in Cx36 2/2 islets upon 100 mmol/L diazoxide but not upon 250 mmol/L diazoxide (Fig. 5B) . Similarly, upon 100 mmol/L diazoxide at 11 mmol/L glucose, insulin secretion from Cx36 2/2 islets was significantly greater than Cx36 +/+ islets. Therefore, in a more general case of K ATP channel opening, a reduction in gap junction coupling elevates [Ca 2+ ] i and insulin secretion. K185Q] islets and control Cx36 2/2 islets ( Fig. 6A and B) . Similar levels of NAD(P)H were observed at elevated glucose in all sets of islets (Fig. 6A) . As a result, Cx36 K185Q] islets showed significantly reduced glucose-stimulated accumulation of NAD(P)H compared with other experimental groups (Fig. 6C) islets at elevated glucose, as indicated by Rhodamine 123 fluorescence (Fig. 6D-F) . Therefore, reducing gap junction coupling in Kir6.2 [DN30, K185Q] -expressing mice leads to an absence of secondary mitochondrial dysfunction.
DISCUSSION
In this study, we tested whether a reduction in islet Cx36 gap junction coupling could compensate for overactive ATP-insensitive K ATP channels in a model of NDM, and therefore prevent the emergence of diabetes. Upon a knockout of Cx36, the elevation in glucose-stimulated [Ca 2+ ] i and insulin secretion that we measured explains the normalization in blood glucose levels. Based on results presented here and prior studies, we propose the following mechanisms of action, schematically represented in Fig. 7A . A reduction in Cx36 gap junctions effectively left shifts the dose response of [Ca 2+ ] i (although insulin remains suppressed at low glucose due to [Ca 2+ ] i -independent mechanisms of suppression [18] ), whereas expression of overactive K ATP channels effectively right shifts the dose response of [Ca 2+ ] i and insulin secretion (with a largely suppressed response over the physiological glucose range in the presence of Cx36). Therefore, in the presence of overactive K ATP channels, a reduction in Cx36 partially normalized the dose response, albeit with disrupted insulin secretion dynamics associated with a loss of Cx36. This is further detailed in Fig. 7B , where in the normal presence of Cx36, inexcitable cells that are present due to heterogeneity prevent membrane depolarization and [Ca 2+ ] i elevations in normally excitable cells at elevated glucose, via a gap ] i at 11 mmol/L glucose in Cx36 +/+ and Cx36 2/2 islets at several diazoxide concentrations. Data averaged over n = 3 age-matched mice in each group, two to five islets per mouse. C: Insulin secretion under high glucose (11 mmol/L) in Cx36 +/+ and Cx36 2/2 islets at several diazoxide concentrations. Data averaged over n = 6 age-matched mice in each group. *Significant difference (P < 0.05, two-tailed Student t test); †significant difference (P < 0.05, one-tailed paired Student t test). Error bars represent mean 6 SEM. junction-mediated current. This suppresses [Ca 2+ ] i elevations and insulin release across the islet. In the absence of Cx36 gap junction coupling, this current is absent (17) and therefore normally excitable cells are free to depolarize, elevate [Ca 2+ ] i , and release insulin at elevated glucose levels. (17, 18) . Here, in the presence overactive ATPinsensitive K ATP channels (Fig. 4) , or diazoxide-induced K ATP channel opening (Fig. 5) , a reduction of gap junction coupling also elevated [Ca 2+ ] i . This shows that a general principle exists whereby gap junction channel closure/ deletion can (at least partially) counteract the effect of K ATP channel opening to elevate [Ca 2+ ] i . Importantly, in the presence of a gain-of-function mutation to the K ATP channels, there was no elevation in [Ca 2+ ] and insulin release at lower glucose levels. As described above, likely a reduction in Cx36 imparts a left shift to the glucose-stimulated [Ca 2+ ] i response rather than a constitutive elevation, counteracting the right shift after ATP-insensitive mutant K ATP channel expression. Thus, a reduction in Cx36 cannot counteract the very strong K ATP opening that results from low glucose and ATP-insensitive K ATP channels. This suggests that a Cx36 gap junction reduction would be unlikely to counteract very strong mutations to the K ATP channel, as is also suggested by very high diazoxide treatment (Fig. 5) .
Interestingly, in islets from Cx36 mice, even those high-GFP + cells that were inexcitable in (Fig. 4) . Electrically uncoupled cells will likely show some stochastic "channel noise," as suggested by modeling studies (23, 24) , which may be sufficient to transiently depolarize and elevate [Ca 2+ ] i . This suggests that electrically uncoupled cells may inherently behave different to b-cells in normal islets, warranting further study.
Importantly, the elevated [Ca 2+ ] i at elevated glucose levels that follows a reduction of gap junction coupling also led to elevated insulin secretion (Figs. 3 and 5 ). This contrasts with the behavior at lower glucose levels in normal islets (18) , where this effect is normally masked due to other mechanisms of cell-cell communication that suppress insulin release independent of [Ca 2+ ] i . However, it was suggested that this other communication mechanism(s) that suppresses insulin is inactive at elevated glucose (18, 25) , as we have demonstrated.
Of further importance, the gap junction-mediated suppression of islet [Ca 2+ ] i and insulin release is physiologically important. By eliminating gap junction coupling in mice expressing ATP-insensitive K ATP channels, we eliminated hyperglycemia (Fig. 1) . Gap junction coupling in the islet has been shown to play an important physiological role: to coordinate and enhance the first phase of insulin secretion and coordinate the pulsatile second phase of insulin secretion (15) . In its absence, glucose intolerance occurs, and we observed glucose intolerance in Cx36 2/2 ;Kir6.2 [DN30, K185Q] mice, albeit slightly less than previously observed (15) , likely due to the younger age of the mice. This physiological role gives a new fundamental understanding of the multicellular properties of the islet, specifically how the electrical coupling of b-cells via gap junction channels can be critically important to coordinate K ATP channel-regulated ] i (dashed black), such that it is largely suppressed within experimental glucose ranges. Insulin follows this dose response. Bottom: In the presence of increased K ATP activity, a reduction in Cx36 activity leads to a left shift in the dose response of [Ca 2+ ] i back to within a physiological range (dashed red), albeit with glucose-stimulated activity slightly blunted compared with a reduction in Cx36 activity alone. Insulin follows this dose response, although at low glucose it is still suppressed due to action of another communication mechanism (dotted red). B: Two representative, neighboring cells in an islet, with one inexcitable cell (intrinsically inexcitable or expressing high levels of ATP-insensitive K ATP channels: lower, green) and one excitable cell (with near-normal K ATP channels: upper, gray). At elevated glucose, the inexcitable cell remains hyperpolarized (V m low). In isolation, the excitable cell would depolarize (V m increase), elevate [Ca 2+ ] i , and release insulin. However, Cx36 gap junction coupling mediates a hyperpolarizing current (I h-pol ) from the inexcitable cell to the excitable cell, preventing depolarization and [Ca 2+ ] i elevations, thereby suppressing Ca 2+ triggering of insulin secretion across the islet. In the absence of Cx36 gap junction coupling, the hyperpolarizing current is abolished and the more excitable cell depolarizes and elevates [Ca 2+ ] i , which triggers insulin secretion.
electrical activity to regulate insulin secretion and glucose homeostasis.
Relevance to Human NDM (4) . Given that a reduction of Cx36 gap junction coupling so dramatically normalized glycemic control, we anticipate an improvement in islet function would occur in humans with NDM. However, some subtle differences must be discussed.
The distribution of Kir6.2 [DN30, K185Q] expression is likely more heterogeneous in islets from this mouse model compared with islets of humans with the disease, due to the stochastic and variable nature of PdxCre ER -mediated recombination (21) . Therefore, the heterogeneity in b-cell function, from which the gap junction-mediated suppression of [Ca 2+ ] i and insulin partly occurs, will not be exactly the same. However, it is well established that human and mouse b-cells lacking cellular proximity are very heterogeneous in their glucose response (27, 28) . This suggests that a Cx36 gap junction reduction will elevate glucose-stimulated [Ca 2+ ] i and insulin even in the presence of uniform Kir6.2 [DN30, K185Q] expression. Results from diazoxide-treated islets (Fig. 5 ) support this, as diazoxide treatment likely provides uniform K ATP opening across the islet. In this case, the endogenous b-cell heterogeneity would be closer to that of human islets with NDM mutations. Further, gap junction coupling suppresses excitability in other conditions of K ATP channel opening at lower glucose levels. In Cx36 2/2 islets, elevated [Ca 2+ ] i is observed in ;50% of b-cells at 5 mmol/L glucose (18) , and in ;40% of b-cells upon 100 mmol/L diazoxide (Fig. 5) , each similar to that after expression of Kir6.2 [DN30, K185Q] (Fig. 4 ). The precise quantitative balance between b-cell heterogeneity and gap junction coupling in determining islet function remains to be determined. Nevertheless, the presence of any heterogeneity will lead to gap junction coupling suppressing [Ca 2+ ] i over a certain range of glucose levels. Likely, the broader the heterogeneity, the greater the difference in the presence and absence of gap junction coupling (18) and the more dramatic the effect in modulating gap junction coupling.
The discovery that NDM can be caused by gain-offunction mutations to the Kir6.2 and Sur1 subunits of the K ATP channel has meant that patients can switch from insulin therapy to oral sulfonylurea treatment with improved glycemic control (7) . Although successful for treating NDM, sulfonylurea treatment has been reported to be associated with hypoglycemic episodes (29) , which may occur due to constitutive glucose-independent K ATP channel closure, which reduces the low glucose regulation of insulin secretion. Chronic sulfonylurea therapy can also cause glucose intolerance (30) , possibly resulting from overstimulation of [Ca 2+ ] i . As discussed above, a modulation of gap junction coupling retains a suppression of [Ca 2+ ] i and insulin secretion at low glucose (Figs. 3, 4, and 7 ) and thus would be anticipated to lessen potential hypoglycemia. More importantly, some Kir6.2 and Sur1 mutations reduce the sensitivity of sulfonylurea inhibition (7, 9, 10) , reducing sulfonylurea effectiveness. We speculate that modulating Cx36 gap junction coupling may provide an alternative route to elevate glucose-stimulated [Ca 2+ ] i and insulin secretion, particularly in the presence of sulfonylurea-insensitive mutations.
Here, a near-complete reduction in gap junction coupling (.95%, Cx36 2/2 ) normalized blood glucose levels, but a partial reduction (;50%, Cx36 +/2 ) had a minimal effect (Supplementary Fig. 1 ). This Cx36 dose response is similar to how reducing Cx36 gap junction coupling disrupts glucose tolerance via firstphase and second-phase insulin dynamics (15) . As a potential therapeutic target, we therefore anticipate that a gap junction inhibition of .50% would be required. Current inhibitors are weak with nonspecific effects, although a recent study developed a novel screen for gap junction modulators (31) , which may yield more potent and specific inhibitors. A partial disruption to gap junction coupling can also result from hyperglycemia (32 (33, 34) and genes that regulate mitochondrial function (35, 36) . Defects in proximal steps could affect the "amplifying" pathways that regulate insulin release (37) , and reduce the effect of gap junction modulation. However, altering the K ATP regulation of membrane potential can compensate for an absence of glucokinase (38) . Therefore, modulating Cx36 gap junction coupling may be more broadly applicable to normalize islet function.
To summarize, we have shown that by reducing gap junction coupling between b-cells in a model of NDM caused by expression of ATP-insensitive K ATP channels, we can eliminate severe hyperglycemia and islet dysfunction. This is achieved through a novel pathway where a reduction in Cx36 can partially compensate for overactive K ATP channels and prevent suppression of electrical activity across the islet. This restores glucose-stimulated [Ca 2+ ] i , insulin secretion, and glucose homeostasis. This yields a better understanding of how the islet functions as a coupled unit of b-cells and may ultimately provide a potential therapeutic target for treating NDM and other monogenic forms of diabetes.
